Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Research & Development: 2020-2024

Historic Research & Development for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $30.3 million.

  • SAB Biotherapeutics' Research & Development rose 14.55% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.3 million, marking a year-over-year increase of 15.42%. This contributed to the annual value of $30.3 million for FY2024, which is 83.18% up from last year.
  • According to the latest figures from FY2024, SAB Biotherapeutics' Research & Development is $30.3 million, which was up 83.18% from $16.5 million recorded in FY2023.
  • Over the past 5 years, SAB Biotherapeutics' Research & Development peaked at $57.2 million during FY2021, and registered a low of $16.5 million during FY2023.
  • Its 3-year average for Research & Development is $27.7 million, with a median of $30.3 million in 2024.
  • As far as peak fluctuations go, SAB Biotherapeutics' Research & Development soared by 104.90% in 2021, and later plummeted by 54.68% in 2023.
  • Yearly analysis of 5 years shows SAB Biotherapeutics' Research & Development stood at $27.9 million in 2020, then spiked by 104.90% to $57.2 million in 2021, then crashed by 36.28% to $36.4 million in 2022, then slumped by 54.68% to $16.5 million in 2023, then spiked by 83.18% to $30.3 million in 2024.